These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36806500)

  • 1. Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?
    Villasco A; Minella C; Bounous VE; Rosso R; Biglia N
    Breast Dis; 2023; 42(1):1-4. PubMed ID: 36806500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
    Abdel-Rahman O
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):885-91. PubMed ID: 27210216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
    Chukir T; Liu Y; Farooki A
    Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for osteoporosis after breast cancer: for whom, why and when.
    Trémollieres FA
    Maturitas; 2014 Nov; 79(3):343-8. PubMed ID: 25308162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
    Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
    Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
    Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
    Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
    Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.